Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Shandong Pharmaceutical Glass Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600529'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.05
Current: 0.05
During the past 13 years, the highest Debt-to-EBITDA Ratio of Shandong Pharmaceutical Glass Co was 0.05. The lowest was 0.00. And the median was 0.00.
SHSE:600529's Debt-to-EBITDA is ranked better than 96.19% of 341
companies
in the Packaging & Containers industry
Industry Median: 2.45
vs SHSE:600529: 0.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shandong Pharmaceutical Glass Co Debt-to-EBITDA Related Terms
Shandong Pharmaceutical Glass Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Pharmaceutical Glass Co Debt-to-EBITDA Chart
SHSE:600529 vs SW, AMCR, PKG: Debt-to-EBITDA Comparison
For the Packaging & Containers subindustry, Shandong Pharmaceutical Glass Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Pharmaceutical Glass Co Debt-to-EBITDA vs Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Shandong Pharmaceutical Glass Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shandong Pharmaceutical Glass Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Shandong Pharmaceutical Glass Co (SHSE:600529) has a Debt-to-EBITDA of 0.05 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Pharmaceutical Glass Co. According to the industry distribution chart, Shandong Pharmaceutical Glass Co ranks #13 out of 341 companies in the Packaging & Containers industry, placing it in the top 3.8%.
Is Shandong Pharmaceutical Glass Co's Debt-to-EBITDA too high?
Shandong Pharmaceutical Glass Co's current Debt-to-EBITDA is 0.05. The Packaging & Containers industry median Debt-to-EBITDA is 2.45. Shandong Pharmaceutical Glass Co's value of 0.05 is 98% below this industry median. Based on the distribution chart, Shandong Pharmaceutical Glass Co ranks #13 out of 341 companies in the Packaging & Containers industry, which is in the top quartile — a strong position relative to peers. Overall, Shandong Pharmaceutical Glass Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Pharmaceutical Glass Co's Debt-to-EBITDA compare to SW and AMCR?
According to the Packaging & Containers industry distribution chart, Shandong Pharmaceutical Glass Co ranks #13 out of 341 companies for Debt-to-EBITDA. This places Shandong Pharmaceutical Glass Co in the top 4% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.45. Shandong Pharmaceutical Glass Co's value of 0.05 is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Packaging & Containers company?
The median Debt-to-EBITDA among Packaging & Containers companies is 2.45, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Pharmaceutical Glass Co's current Debt-to-EBITDA of 0.05 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Pharmaceutical Glass Co. For the Packaging & Containers industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Pharmaceutical Glass Co's current Debt-to-EBITDA is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Pharmaceutical Glass Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co (SHSE:600529) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.29, compared to a current price of ¥18.31 — trading 21.4% below its estimated fair value. The current Debt-to-EBITDA is 0.05 and 98% below the Packaging & Containers industry median of 2.45. Shandong Pharmaceutical Glass Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shandong Pharmaceutical Glass Co (SHSE:600529), the current Debt-to-EBITDA is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Pharmaceutical Glass Co (SHSE:600529) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co stock appears to be undervalued.
The current stock price of ¥18.31 is trading 21.4% below its estimated GF Value™ of ¥23.29.
GuruFocus considers Shandong Pharmaceutical Glass Co to be Modestly Undervalued.
Key valuation signals for SHSE:600529:
Debt-to-EBITDA: 0.05
GF Value™: ¥23.29 vs. price of ¥18.31 (21.4% below fair value)
Industry Position: 98% below the Packaging & Containers median (#13 of 341)
No single metric tells the full story. See the SHSE:600529 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Pharmaceutical Glass Co Ltd is a pharmaceutical glass packaging product company. Its pharmaceutical glass packaging products and butyl rubber series products which service object of pharmaceutical, food, daily necessities industries. The products include for moulded injection vial for antibiotics series, tubular glass vial series, amber glass bottle series, neutral borosilicate glass bottle series, infusion bottle series, cosmetic bottles series, food bottles series, butyl rubber stopper series, prefillable syringes series, and aluminum-plastic cap series.
92GF Score
Get the complete analysis for SHSE:600529
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600529 has been successfully added to your 
